Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial.
alkylator chemotherapy
pediatric sarcoma
radiotherapy
rhabdomyosarcoma
surgical resection
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
26 Jul 2024
26 Jul 2024
Historique:
revised:
04
06
2024
received:
09
11
2023
accepted:
10
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS. Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.
Sections du résumé
BACKGROUND
BACKGROUND
The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS).
PATIENTS AND METHODS
METHODS
Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m
RESULTS
RESULTS
From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non-bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5-81.6) and 93.5% (95% CI, 90.1-95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS.
CONCLUSIONS
CONCLUSIONS
Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione Città della Speranza
Organisme : Alice's Arc Children's Cancer Charity
Informations de copyright
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Pastore G, Peris‐Bonet R, Carli M, Martínez‐García C, de Toledo JS, Steliarova‐Foucher E. Childhood soft tissue sarcomas incidence and survival in European children (1978‐1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2136‐2149. doi:10.1016/j.ejca.2006.05.016
Stiller CA, Stevens MCG, Magnani C, Corazziari I. Survival of children with soft‐tissue sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer. 2001;37(6):767‐774. doi:10.1016/S0959‐8049(01)00007‐7
Skapek SX, Ferrari A, Gupta AA, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5(1):1. doi:10.1038/s41572‐018‐0051‐2
Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children? Cancer. 2007;110(11):2561‐2567. doi:10.1002/cncr.23079
Cecchetto G, Bisogno G, Treuner J, et al. Role of surgery for nonmetastatic abdominal rhabdomyosarcomas. Cancer. 2003;97(8):1974‐1980. doi:10.1002/cncr.11285
Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six‐drug versus standard three‐drug chemotherapy for high‐risk nonmetastatic rhabdomyosarcoma and other chemotherapy‐sensitive childhood soft tissue sarcomas: long‐term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30(20):2457‐2465. doi:10.1200/JCO.2011.40.3287
Stevens MCG, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23(12):2618‐2628. doi:10.1200/JCO.2005.08.130
Koscielniak E, Jürgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer. 1992;70(10):2557‐2567. doi:10.1002/1097‐0142(19921115)70:10<2557::aid‐cncr2820701027>3.0.co;2‐8
Rudzinski ER, Anderson JR, Hawkins DS, Skapek SX, Parham DM, Teot LA. The World Health Organization classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the Children’s Oncology Group. Arch Pathol Lab Med. 2015;139(10):1281‐1287. doi:10.5858/arpa.2014‐0475‐OA
Oberlin O, Rey A, Anderson J, et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment ‐ results of an international workshop. J Clin Oncol. 2001;19(1):197‐204. doi:10.1200/JCO.2001.19.1.197
Oberlin O, Rey A, Sanchez De Toledo J, et al. Randomized comparison of intensified six‐drug versus standard three‐drug chemotherapy for high‐risk nonmetastatic rhabdomyosarcoma and other chemotherapy‐sensitive childhood soft tissue sarcomas: long‐term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30(20):2457‐2465. doi:10.1200/JCO.2011.40.3287
Stevens MCG, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology‐SIOP malignant mesenchymal tumor 89. J Clin Oncol. 2005;23(12):2618‐2628. doi:10.1200/JCO.2005.08.130
Minard‐Colin V, Walterhouse D, Bisogno G, et al. Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups. Pediatr Blood Cancer. 2018;65(9). doi:10.1002/pbc.27096
Cecchetto G, Carretto E, Bisogno G, et al. Complete second look operation and radiotherapy in locally advanced non‐alveolar rhabdomyosarcoma in children: a report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer. 2008;51(5):593‐597. doi:10.1002/PBC.21702
Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017;390(10112):2569‐2582. doi:10.1016/S0140‐6736(17)31610‐0
Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, Pappo AS. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Eur J Cancer. 2004;40(12):1878‐1885. doi:10.1016/j.ejca.2004.04.005
Bergeron C, Jenney M, de Corti F, et al. Embryonal rhabdomyosarcoma completely resected at diagnosis: the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 experience. Eur J Cancer. 2021;146:21‐29. doi:10.1016/j.ejca.2020.12.025
Green DM, Liu W, Kutteh WH, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15(11):1215‐1223. doi:10.1016/S1470‐2045(14)70408‐5
Hawkins DS, Chi YY, Anderson JR, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate‐risk rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol. 2018;36(27):2770‐2777. doi:10.1200/JCO.2018.77.9694
Spalding AC, Hawkins DS, Donaldson SS, et al. The effect of radiation timing on patients with high‐risk features of parameningeal rhabdomyosarcoma: an analysis of IRS‐IV and D9803. Int J Radiat Oncol Biol Phys. 2013;87(3):512‐516. doi:10.1016/j.ijrobp.2013.07.003
Hawkins DS, Bisogno G, Koscielniak E. Introducing INSTRuCT: an international effort to promote cooperation and data sharing. Pediatr Blood Cancer. 2020;70(3). doi:10.1002/pbc.28701
Orbach D, Mosseri V, Gallego S, et al. Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. Head Neck. 2017;39(1):24‐31. doi:10.1002/hed.24547
Réguerre Y, Martelli H, Rey A, et al. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP‐MMT) Committee. Eur J Cancer. 2012;48(13):2020‐2027. doi:10.1016/j.ejca.2011.11.011
Dehner CA, Rudzinski ER, Davis JL. Rhabdomyosarcoma: updates on classification and the necessity of molecular testing beyond immunohistochemistry. Hum Pathol. 2023;147:72‐81. doi:10.1016/j.humpath.2023.12.004
Lautz TB, Chi YY, Li M, et al. Benefit of delayed primary excision in rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer. 2021;127(2):275‐283. doi:10.1002/cncr.33275